Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.4.0.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Operating activities    
Net income including noncontrolling interests $ 6,608 $ (89)
Less: gain from discontinued operations 731 0
Income (loss) from operations 5,877 (89)
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:    
Non-cash change in estimated fair value of contingent liabilities 1,306 3
Realized gain on sale of short-term investment (406) 447
Depreciation and amortization 2,575 650
Amortization of discount on investments, net 320 0
Amortization of debt discount and issuance fees 2,668 2,509
Stock-based compensation 4,118 2,914
Deferred income taxes 4,101 6
Accretion of note payable 0 14
Change in fair value of the convertible debt receivable from Viking 15 0
Loss on equity investment in Viking Therapeutics, Inc. $ 1,605 0
Other (1)
Changes in operating assets and liabilities:    
Accounts receivable $ (5,604) 5,211
Inventory 853 (150)
Other current assets 16 445
Other long-term assets (41) (291)
Accounts payable and accrued liabilities (4,302) (4,667)
Restricted investments 0 661
Deferred revenue 13 (83)
Net cash provided by operating activities 13,114 7,579
Investing activities    
Payments to CVR holders and other contingency payments (5,446) (3,247)
Purchases of property and equipment (238) (10)
Cash paid for acquisition, net of cash acquired (92,855) 0
Purchase of short-term investments (49,892) 0
Proceeds from sale of property and equipment 0 1
Proceeds from sale of short-term investments 20,270 459
Proceeds from maturity of short-term investments 48,401 0
Net cash used in investing activities (79,760) (2,797)
Financing activities    
Net proceeds from stock option exercises and ESPP 1,013 781
Purchase of common stock for RSU vesting (502) 0
Net cash provided by financing activities 511 781
Net (decrease) increase in cash and cash equivalents (66,135) 5,563
Cash and cash equivalents at beginning of period 97,428 160,203
Cash and cash equivalents at end of period 31,293 165,766
Supplemental disclosure of cash flow information    
Interest paid 919 903
Taxes paid 1 11
Supplemental schedule of non-cash activity    
Stock issued for acquisition (77,615) 0
Accrued Inventory Purchases 600 2,402
Unrealized gain on AFS investments $ (1,834) $ 4,614